Enterovirus 71 meningoencephalitis complicating rituximab therapy. 2011

Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, University of Sydney, Sydney, Australia.

We describe a fatal case of proven enterovirus 71 meningoencephalitis complicating monoclonal anti-CD20 antibody therapy for non-Hodgkin's lymphoma. B-cell depletion, an effective treatment strategy in an expanding spectrum of hematological and inflammatory disorders, impairs neutralising antibody-mediated clearance of enterovirus. The global threat of emerging neurotropic viruses such as enterovirus 71 is heightened by an increasing pool of susceptible individuals in non-endemic regions.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D008590 Meningoencephalitis An inflammatory process involving the brain (ENCEPHALITIS) and meninges (MENINGITIS), most often produced by pathogenic organisms which invade the central nervous system, and occasionally by toxins, autoimmune disorders, and other conditions. Cerebromeningitis,Encephalomeningitis,Cerebromeningitides,Encephalomeningitides,Meningoencephalitides
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004769 Enterovirus Infections Diseases caused by ENTEROVIRUS. Infections, Enterovirus,Enterovirus Infection,Infection, Enterovirus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069283 Rituximab A murine-derived monoclonal antibody and ANTINEOPLASTIC AGENT that binds specifically to the CD20 ANTIGEN and is used in the treatment of LEUKEMIA; LYMPHOMA and RHEUMATOID ARTHRITIS. CD20 Antibody, Rituximab,GP2013,IDEC-C2B8,IDEC-C2B8 Antibody,Mabthera,Rituxan,IDEC C2B8,IDEC C2B8 Antibody,Rituximab CD20 Antibody
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D058846 Antibodies, Monoclonal, Murine-Derived Antibodies obtained from a single clone of cells grown in mice or rats. Murine-Derived Monoclonal Antibodies,Antibodies, Murine-Derived Monoclonal,Monoclonal Antibodies, Murine-Derived,Murine Derived Monoclonal Antibodies
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
November 2016, The Pediatric infectious disease journal,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
August 2013, Emerging infectious diseases,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
April 2022, Journal of neurovirology,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
November 2023, Neurology(R) neuroimmunology & neuroinflammation,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
December 2015, Jundishapur journal of microbiology,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
August 2007, Journal of pediatric hematology/oncology,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
May 1980, Orvosi hetilap,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
July 2016, Expert review of vaccines,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
March 2015, Microbiology and immunology,
Rebekah Ahmed, and Michael Buckland, and Leo Davies, and G Michael Halmagyi, and Shannon L Rogers, and Steven Oberste, and Michael H Barnett
September 2021, Journal of neuroimmunology,
Copied contents to your clipboard!